Rituximab for Low Tumor Burden Follicular Lymphoma | Noriko Fukuhara MD, PhD | #ASH24

Rituximab for Low Tumor Burden Follicular Lymphoma | Noriko Fukuhara MD, PhD | #ASH24
Positive Loncastuximab & Rituximab Results in R/R Follicular Lymphoma | Juan Alderuccio, MD | #ASH24
Treatment Outcomes for LBCL with Central Nervous System Involvement | Juan Alderuccio, MD | #ASH24
Venetoclax + Pola-R-CHP for High-Risk B-Cell Lymphoma | Catherine Diefenbach, MD | #ASH24
Glofit-R-ICE for Patients with Relapsed/Refractory DLBCL | Catherine Diefenbach, MD | #ASH24
Bispecific Antibody Use After CAR-T Failure for B-Cell Lymphoma | Megan Melody, MD, MS | #ASH24
Safety of CAR-T Therapy, Tisa-cel, for DLBCL | Christian Chabannon, MD, PhD | #ASH24
Moving the Diffuse Large B-Cell Lymphoma Field Forward | Matthew Matasar, MD | #ASH24
Safety & Efficacy of Odronextamab for DLBCL After CAR-T Failure | Matthew Matasar, MD | #ASH24
Ketogenic Diet During CAR-T Therapy for DLBCL | Christopher D'Angelo, MD | #ASH24
Boom-Boom Radiation as Bridging Therapy Prior to CAR-T for DLBCL | Christopher D'Angelo, MD | #ASH24
Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24
Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma | Andrew Portugese | #ASH24
What is smoldering (asymptomatic) multiple myeloma?
Adding Isatuximab to Standard RVD May Improve Outcomes for Myeloma Patients | Elias Mai, MD | #ASH24
Inobrodib in Combination with Pomalidomide and Dexamethasone in Myeloma | Emma Searle, MD | #ASH24
Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD | #ASH24
Combination of Isatuximab, Carfilzomib, Lenalidomide, Dex in Myeloma | Elizabeth O'Donnell | #ASH24